

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Katia Vancompernelle

Serial No.: To be assigned

Filed: July 30, 2003

For: PHOSPHORYLATED GLYOXALASE
I AND ITS USE

Examiner: To be assigned

Group Art Unit: To be assigned

Attorney Docket No.: 2676-6045US

NOTICE OF EXPRESS MAILING

Express Mail Mailing Label Number: EV348041492US

Date of Deposit with USPS: July 30, 2003

Person making Deposit: Matthew Wooton

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In compliance with the duty to disclose information material to patentability pursuant to 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 or PTO/SB/08 be considered by the Examiner and made of record. Copies of the listed documents are enclosed pursuant to 37 C.F.R. § 1.98(a).

In accordance with 37 C.F.R. § 1.97(g) and (h), filing of this Information Disclosure Statement is not to be construed as a representation that a search has been made or an admission that the information cited herein is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b). Further, no representation is made by Applicant herein that no other possible material information as defined in 37 C.F.R. § 1.56(b) exists.

Foreign Patent Documents

<u>Document No.</u>	<u>Publication Date</u>	<u>Patentee</u>
WO 02/061065	08-08-2002	Vlaams Interuniversitair Instituut Voor Biotechnologie

Other Documents

Patent Abstracts of Japan, 1993, 1 page.

GUY et al., Interleukin 1 and Tumor Necrosis Factor Activate Common Multiple Protein Kinases in Human Fibroblasts, The Journal of Biological Chemistry, 1991, pp. 14343-52, Vol. 266, No. 22.

INOUE et al., Secual Response of Saccharomyces cerevisiae: Phosphorylation of Yeast Glyoxalase I by a Cell Extract of Mating Factor-Treated Cells, J. Biochem, 1990, pp. 4-6, Vol. 108.*

KIM et al., Human Glyoxalase I, The Journal of Biological Chemistry, 1993, pp. 11217-21, Vol. 268, No. 15.

RANGANATHAN et al., The Journal of Biological Chemistry, 1993, pp. 5661-67, Vol. 268, No. 8.

SAKAMOTO et al., Glyoxalase I is involved in resistance of human leukemia cells to antitumor agent-induced apoptosis, Blood, May 15, 2000, pp. 3214-18, Vol. 95, No. 10.

THORNALLEY et al., Advances in glyoxalase research. Glyoxalase expression in malignancy, anti-proliferative effects of methylglyoxal, glyoxalase I inhibitor diesters and S-D-lactoylglutathione, and methylglyoxal-modified protein binding and endocytosis by the advanced glycation endproduct receptor, Critical Reviews in Oncology/Hematology, 1995, pp. 99-128, Vol. 20.

VAN HERREWEGHE et al., Tumor necrosis factor-induced modulation of glyoxalase I activities through phosphorylation by PKA results in cell death and is accompanied by the formation of a specific methylglyoxal-derived AGE, Proceedings of the National Academy of Sciences of the United States, January 22, 2002, pp. 949-54, Vol. 99, No. 2.

PCT International Search Report, PCT/EP02/01118, dated December 11, 2002.

Attorney Docket No.: 2676-6045US

*Only page 4 of this article has been provided. The remainder will be provided as soon as possible.

This Information Disclosure Statement is filed within three (3) months of the filing date of the above-identified application, and no certification pursuant to 37 C.F.R. § 1.97(c) or a fee pursuant to 37 C.F.R. § 1.17(p) is required.

Respectfully submitted,



Bretton L. Crockett
Registration No. 44,632
Attorney for Applicant(s)
TRASKBRITT, P.C.
P.O. Box 2550
Salt Lake City, Utah 84110-2550
Telephone: 801-532-1922

Date: July 30, 2003
BLC/bv

Enclosures: Form PTO-1449 or PTO/SB/08
Cited Documents

Document in ProLaw

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			<i>Complete if Known</i>		
			Application Number	To be assigned	
			Filing Date	July 30, 2003	
			First Named Inventor	Katia Vancompernelle	
			Group Art Unit	To be assigned	
			Examiner Name	To be assigned	
			Attorney/DoCKET Number	2676-6045US	
Sheet	1	of	2		

[illegible][illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2

of

2

Complete if Known

Application Number	To be assigned
Filing Date	July 30, 2003
First Named Inventor	Katia Vancompernelle
Group Art Unit	To be assigned
Examiner Name	To be assigned
Attorney Docket Number	2676-6045US

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Patent Abstracts of Japan, 1993, 1 page.	
		GUY et al., Interleukin 1 and Tumor Necrosis Factor Activate Common Multiple Protein Kinases in Human Fibroblasts, The Journal of Biological Chemistry, 1991, pp. 14343-52, Vol. 266, No. 22.	
		INOUE et al., Secual Response of Saccharomyces cerevisiae: Phosphorylation of Yeast Glyoxalase I by a Cell Extract of Mating Factor-Treated Cells, J. Biochem, 1990, pp. 4-6, Vol. 108.*	
		KIM et al., Human Glyoxalase I, The Journal of Biological Chemistry, 1993, pp. 11217-21, Vol. 268, No. 15.	
		RANGANATHAN et al., The Journal of Biological Chemistry, 1993, pp. 5661-67, Vol. 268, No. 8.	
		SAKAMOTO et al., Glyoxalase I is involved in resistance of human leukemia cells to antitumor agent-induced apoptosis, Blood, May 15, 2000, pp. 3214-18, Vol. 95, No. 10.	
		THORNALLEY et al., Advances in glyoxalase research. Glyoxalase expression in malignancy, anti-proliferative effects of methylglyoxal, glyoxalase I inhibitor diesters and S-D-lactoylglutathione, and methylglyoxal-modified protein binding and endocytosis by the advanced glycation endproduct receptor, Critical Reviews in Oncology/Hematology, 1995, pp. 99-128, Vol. 20.	
		VAN HERREWEGHE et al., Tumor necrosis factor-induced modulation of glyoxalase I activities through phosphorylation by PKA results in cell death and is accompanied by the formation of a specific methylglyoxal-derived AGE, Proceedings of the National Academy of Sciences of the United States, January 22, 2002, pp. 949-54, Vol. 99, No. 2.	
		PCT International Search Report, PCT/EP02/01118, dated December 11, 2002.	
		*Only page 4 of this article has been provided. The remainder will be provided as soon as possible.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.